Hansa Biopharma and Medison Pharma announce positive reimbursement decision in Poland for Idefirix® in highly sensitized kidney transplant patients
Idefirix® (imlifidase) becomes the first and only product reimbursed for the desensitization of highly sensitized patients waiting for a kidney transplant in Poland Reimbursement follows the inclusion of Idefirix® on the shortlist for exceptional innovative treatments with special funding The reimbursement decision provides highly sensitized patients in Poland access to Idefirix® to enable kidney transplantation from September 1st, 2022 LUND, Sweden and PETACH […]
Medison Pharma Announces the Expansion of its Partnership with Albireo to a Multi-Regional Agreement to Commercialize Odevixibat in Canada and Israel
PETACH TIKVAH, Israel, Aug. 16, 2022 /PRNewswire/ — Medison Pharma (“Medison”), a global pharma company focused on providing access to highly innovative therapies to patients in international markets, announced today the expansion of its partnership with Albireo to a multi-regional agreement to commercialize Odevixibat in Canada and Israel, for the treatment of patients with cholestatic liver diseases. “Albireo’s vote of confidence in the commercial solution […]
Medison Pharma Announces Multi-Regional Partnership Agreement with argenx to Commercialize Efgartigimod Across Europe and Israel
PETACH TIKVAH, Israel, June 6, 2022 /PRNewswire/ — Medison Pharma (“Medison”), a global pharma company focused on providing access to highly innovative therapies to patients in international markets, announced today an exclusive multi-regional agreement with argenx to commercialize efgartigimod in 14 countries, including Poland, Hungary, Slovenia, Czech Republic, Romania, Bulgaria, Lithuania, Croatia, Slovakia, Estonia, Latvia, Greece, Cyprus, and Israel, for the treatment of adult patients with generalized myasthenia gravis. “We are on a mission to help […]
Medison Pharma Announces Extension of Multi-territorial Agreement with Immunocore and Expansion into Australia and New Zealand
The latest geographic growth increases Medison’s global footprint across 25 countries in four continents, further strengthening its commercial offering PETACH TIKVAH, Israel, May 23, 2022 /PRNewswire/ — Medison Pharma (“Medison”), a global pharma company focused on providing access to highly innovative therapies to patients in international markets, today announced the addition of new markets to its multi-territorial agreement with Immunocore Holdings […]
Hansa Biopharma and Medison Pharma announce marketing authorization in Israel for Idefirix[®] (imlifidase) for desensitization treatment of highly sensitized kidney transplant patients
Israel is the first market outside of Europe to grant regulatory approval for Idefirix® The decision by Israel’s regulatory authority provides highly sensitized patients in Israel with the opportunity to receive Idefirix® as desensitization treatment The approval to use Idefirix® as defined in indication approved by the European Medicines Agency (EMA)1,2 Lund, Sweden and Petach Tikva, Israel […]
BeiGene and Medison Announce Approval and National Reimbursement in Israel for BRUKINSA® (zanubrutinib) for the Treatment of Waldenström’s Macroglobulinemia
Second Regulatory Approval for BRUKINSA in Israel March 15, 2022 08:00 AM Eastern Daylight Time PETACH TIKVA, Israel & CAMBRIDGE, Mass. & BEIJING & BASEL, Switzerland–(BUSINESS WIRE)–BeiGene (NASDAQ: BGNE; HKEX: 06160, SSE: 688235), a global, science-driven biotechnology company focused on developing innovative and affordable medicines to improve treatment outcomes and access for patients worldwide, and […]
Victor Papamoniodis Joins Medison Pharma as VP International Markets
ZUG, Switzerland, Jan. 20, 2022 /PRNewswire/ — Medison, a global pharma company focused on providing access to highly innovative therapies to patients in international markets (“Medison”), is proud to announce the joining of Victor Papamoniodis in the newly created position of VP International Markets. Victor will be based in Zug, Switzerland, Medison’s international headquarters. Victor will head Medison’s markets outside of Israel and will focus on scaling up the […]
Hansa Biopharma and Medison Pharma announce multiregional commercialization partnership for Hansa’s desensitization treatment for kidney transplant in Central Eastern Europe and Israel
LUND, Sweden and PETACH TIKVA, Israel, Dec. 7, 2021 /PRNewswire/ — Hansa Biopharma AB, “Hansa” (Nasdaq Stockholm: HNSA), a pioneer in enzyme technology for rare immunological conditions, and Medison Pharma, a global pharma company focused on providing access to highly innovative therapies to patients in international markets (“Medison”), today announce a multiregional agreement for Medison to commercialize Hansa’s desensitization treatment for […]
Immunocore and Medison Pharma Partner for Future Commercialization of Tebentafusp in Canada, Central Eastern Europe, and Israel
Immunocore and Medison Pharma Partner for Future Commercialization of Tebentafusp in Canada, Central Eastern Europe, and Israel (OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & ROCKVILLE, Md., US and PETACH TIKVAH, Israel, October 18, 2021) — Immunocore (Nasdaq: IMCR), a late-stage biotechnology company pioneering the development of a novel class of T cell receptor (TCR) bispecific immunotherapies designed to treat a broad range of diseases, including cancer, […]
Rhythm Pharmaceuticals and Medison Pharma Partner to Commercialize IMCIVREE™ (setmelanotide) in Israel
BOSTON and PETACH TIKVA, Israel, July 22, 2021 (GLOBE NEWSWIRE) — Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company committed to transforming the care of people living with rare genetic diseases of obesity, and Medison Pharma, a leading commercial partner for highly innovative therapies in international markets, today announced an exclusive distribution agreement for Medison […]